PCBD2

Across TCGA pan-cancer cohorts, PCBD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCBD2 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PCBD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCBD2 expression acts as an unfavorable survival marker.

KIRC, BLCA, and ACC are the cancer types where PCBD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.266	0.805	.017	12	view →
BLCA	DFS	Median	III,IV	0.109	0.575	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCBD2–KIRC (OS)

Open the KIRC breakdown →